These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 26164165)

  • 21. Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume. A serial CT scan-based study.
    Werner-Wasik M; Xiao Y; Pequignot E; Curran WJ; Hauck W
    Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):56-61. PubMed ID: 11516851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modified response evaluation criteria in solid tumors: A better response evaluation criteria for patients with non-squamous non-small cell lung cancer after bevacizumab treatment.
    Huang Y; Yang Y; Qu A; Li S; Chen D; Zou H; Li S; Zhang Y; Zhuang W; Su J; Zhou X; Zhang Y
    Asia Pac J Clin Oncol; 2024 Feb; 20(1):101-108. PubMed ID: 37898825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non-Small Cell Lung Cancer.
    Beer L; Hochmair M; Haug AR; Schwabel B; Kifjak D; Wadsak W; Fuereder T; Fabikan H; Fazekas A; Schwab S; Mayerhoefer ME; Herold C; Prosch H
    Clin Nucl Med; 2019 Jul; 44(7):535-543. PubMed ID: 31021918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer.
    Crabb SJ; Patsios D; Sauerbrei E; Ellis PM; Arnold A; Goss G; Leighl NB; Shepherd FA; Powers J; Seymour L; Laurie SA
    J Clin Oncol; 2009 Jan; 27(3):404-10. PubMed ID: 19047292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST).
    Jiang T; Kambadakone A; Kulkarni NM; Zhu AX; Sahani DV
    Invest Radiol; 2012 Jan; 47(1):11-7. PubMed ID: 21512396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison Between
    Rossi G; Bauckneht M; Genova C; Rijavec E; Biello F; Mennella S; Dal Bello MG; Cittadini G; Bruzzi P; Piva R; Ceriani V; Sambuceti G; Lopci E; Morbelli S; Grossi F
    J Nucl Med; 2020 Jul; 61(7):990-998. PubMed ID: 31806768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy.
    William WN; Pataer A; Kalhor N; Correa AM; Rice DC; Wistuba II; Heymach J; Lee JJ; Kim ES; Munden R; Gold KA; Papadimitrakopoulou V; Swisher SG; Erasmus JJ;
    J Thorac Oncol; 2013 Feb; 8(2):222-8. PubMed ID: 23287849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in non-small cell lung cancer.
    Lee HY; Lee HJ; Kim YT; Kang CH; Jang BG; Chung DH; Goo JM; Park CM; Lee CH; Kang KW
    J Thorac Oncol; 2010 Apr; 5(4):497-503. PubMed ID: 20195167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response criteria in solid tumors (PERCIST/RECIST) and SUV
    Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
    Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Texture features of colorectal liver metastases on pretreatment contrast-enhanced CT may predict response and prognosis in patients treated with bevacizumab-containing chemotherapy: a pilot study including comparison with standard chemotherapy.
    Ravanelli M; Agazzi GM; Tononcelli E; Roca E; Cabassa P; Baiocchi G; Berruti A; Maroldi R; Farina D
    Radiol Med; 2019 Sep; 124(9):877-886. PubMed ID: 31172448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predicting Overall Survival in Patients With Metastatic Melanoma on Antiangiogenic Therapy and RECIST Stable Disease on Initial Posttherapy Images Using CT Texture Analysis.
    Smith AD; Gray MR; del Campo SM; Shlapak D; Ganeshan B; Zhang X; Carson WE
    AJR Am J Roentgenol; 2015 Sep; 205(3):W283-93. PubMed ID: 26295664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy.
    Nishino M; Jackman DM; Hatabu H; Yeap BY; Cioffredi LA; Yap JT; Jänne PA; Johnson BE; Van den Abbeele AD
    AJR Am J Roentgenol; 2010 Sep; 195(3):W221-8. PubMed ID: 20729419
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CT Volumetry and Basic Texture Analysis as Surrogate Markers in Advanced Non-small-cell Lung Cancer.
    Owen B; Gandara D; Kelly K; Moore E; Shelton D; Knollmann F
    Clin Lung Cancer; 2020 May; 21(3):225-231. PubMed ID: 31699509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic implications of volume-based measurements on FDG PET/CT in stage III non-small-cell lung cancer after induction chemotherapy.
    Soussan M; Chouahnia K; Maisonobe JA; Boubaya M; Eder V; Morère JF; Buvat I
    Eur J Nucl Med Mol Imaging; 2013 May; 40(5):668-76. PubMed ID: 23306807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fractal analysis of CT perfusion images for evaluation of antiangiogenic treatment and survival in hepatocellular carcinoma.
    Hayano K; Lee SH; Yoshida H; Zhu AX; Sahani DV
    Acad Radiol; 2014 May; 21(5):654-60. PubMed ID: 24703479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Texture analysis of advanced non-small cell lung cancer (NSCLC) on contrast-enhanced computed tomography: prediction of the response to the first-line chemotherapy.
    Ravanelli M; Farina D; Morassi M; Roca E; Cavalleri G; Tassi G; Maroldi R
    Eur Radiol; 2013 Dec; 23(12):3450-5. PubMed ID: 23835926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiologic Pseudoprogression during Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Katz SI; Hammer M; Bagley SJ; Aggarwal C; Bauml JM; Thompson JC; Nachiappan AC; Simone CB; Langer CJ
    J Thorac Oncol; 2018 Jul; 13(7):978-986. PubMed ID: 29738824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Revised Choi imaging criteria correlate with clinical outcomes in patients with metastatic renal cell carcinoma treated with sunitinib.
    Thian Y; Gutzeit A; Koh DM; Fisher R; Lote H; Larkin J; Sohaib A
    Radiology; 2014 Nov; 273(2):452-61. PubMed ID: 24869795
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging.
    Anzidei M; Napoli A; Zaccagna F; Cartocci G; Saba L; Menichini G; Cavallo Marincola B; Marotta E; Di Mare L; Catalano C; Passariello R
    J Comput Assist Tomogr; 2011; 35(6):690-6. PubMed ID: 22082538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The comparison of prognostic value of tumour volumetric regression ratio and RECIST 1.1 criteria after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Zeng YY; Xiang ZZ; He T; Liu F; Shao BF; Yan RN; Ma JC; Wang XR; Liu L
    Oral Oncol; 2020 Dec; 111():104924. PubMed ID: 32736209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.